NR 507 EDAPT WEEK 5 SCHIZOPHRENIA ADVANCED
PATHOPHYSIOLOGY
(CHAMBERLAIN UNIVERSITY)
NR 507 EDAPT WEEK 5
SCHIZOPHRENIA, CH 19, PG
618
,NR 507 Edapt Week 5 Schizophrenia, Ch 19, Pg 618
Untreated schizophrenia presents the inability to connect with a client’s surrounding
environment, usually due to hallucinations or delusions.
Significant complaints of anhedonia are more likely with major depressive or bipolar
disorder. Excessive energy describes a mania in someone with bipolar disorder. Intense fear
that produces sympathetic nervous system symptoms is usually caused by a panic
disorder.
, Dysregulation of dopamine and glutamate are contributors to the clinical manifestations
experienced by someone with schizophrenia.
Acetylcholine dysregulation is seen in conditions like dementia. Serotonin and norepinephrine
dysregulation are seen in conditions like depression and other mood disorders.
Pathophysiology of
Schizophrenia
Schizophrenia is a complex, chronic mental disorder characterized by an array of
symptoms, including delusions, hallucinations, disorganized speech, and
impaired cognitive function. The exact pathophysiology remains unclear but likely
involves a combination of genetic, chemical, and environmental factors.
An imbalance of the neurotransmitter dopamine in different areas of the brain is
believed to cause many of the symptoms of schizophrenia. Structural brain
abnormalities, including changes in the volume of certain brain regions and
altered neural connectivity, are also observed in studies.
Dopamine is an important neurotransmitter and plays a major role in the
regulation of behavior, mood, motivation, and motor control. Of the five
types of dopamine receptors, the D1 family (D1 and D5) are located in the
frontal cortex, caudate, putamen, and nucleus accumbens. The D2 family
(D2, D3, and D4) are primarily located in the basal ganglia, hippocampus,
thalamus, cerebellum, and cerebral cortex.
Another neurotransmitter that plays a role in schizophrenia is glutamate.
Studies have found lower levels of glutamate in the cerebral spinal fluid and other
areas of the brain in people with schizophrenia. Drugs that block glutamate activity, like
ketamine, can cause symptoms like schizophrenia in people who do not have the
illness.
Schizophrenia Risk Factors
The etiology of schizophrenia is multifactorial and may involve both genetic and
environmental influences. A family history of schizophrenia significantly increases the risk
of symptom onset, indicating a genetic component. Environmental factors during
pregnancy, such as maternal infections, malnutrition, or stress, also add additional risk.
Other factors include advanced paternal age at the time of conception, childhood
trauma, and substance abuse (e.g., cannabis), especially during adolescence.
Social determinants of health (SDOH) may play a role in the development of this
condition. For example, clients of lower socioeconomic status or those forced to live in
areas of high chemical contamination or food deserts are more likely to experience or
have children who experience schizophrenia.
PATHOPHYSIOLOGY
(CHAMBERLAIN UNIVERSITY)
NR 507 EDAPT WEEK 5
SCHIZOPHRENIA, CH 19, PG
618
,NR 507 Edapt Week 5 Schizophrenia, Ch 19, Pg 618
Untreated schizophrenia presents the inability to connect with a client’s surrounding
environment, usually due to hallucinations or delusions.
Significant complaints of anhedonia are more likely with major depressive or bipolar
disorder. Excessive energy describes a mania in someone with bipolar disorder. Intense fear
that produces sympathetic nervous system symptoms is usually caused by a panic
disorder.
, Dysregulation of dopamine and glutamate are contributors to the clinical manifestations
experienced by someone with schizophrenia.
Acetylcholine dysregulation is seen in conditions like dementia. Serotonin and norepinephrine
dysregulation are seen in conditions like depression and other mood disorders.
Pathophysiology of
Schizophrenia
Schizophrenia is a complex, chronic mental disorder characterized by an array of
symptoms, including delusions, hallucinations, disorganized speech, and
impaired cognitive function. The exact pathophysiology remains unclear but likely
involves a combination of genetic, chemical, and environmental factors.
An imbalance of the neurotransmitter dopamine in different areas of the brain is
believed to cause many of the symptoms of schizophrenia. Structural brain
abnormalities, including changes in the volume of certain brain regions and
altered neural connectivity, are also observed in studies.
Dopamine is an important neurotransmitter and plays a major role in the
regulation of behavior, mood, motivation, and motor control. Of the five
types of dopamine receptors, the D1 family (D1 and D5) are located in the
frontal cortex, caudate, putamen, and nucleus accumbens. The D2 family
(D2, D3, and D4) are primarily located in the basal ganglia, hippocampus,
thalamus, cerebellum, and cerebral cortex.
Another neurotransmitter that plays a role in schizophrenia is glutamate.
Studies have found lower levels of glutamate in the cerebral spinal fluid and other
areas of the brain in people with schizophrenia. Drugs that block glutamate activity, like
ketamine, can cause symptoms like schizophrenia in people who do not have the
illness.
Schizophrenia Risk Factors
The etiology of schizophrenia is multifactorial and may involve both genetic and
environmental influences. A family history of schizophrenia significantly increases the risk
of symptom onset, indicating a genetic component. Environmental factors during
pregnancy, such as maternal infections, malnutrition, or stress, also add additional risk.
Other factors include advanced paternal age at the time of conception, childhood
trauma, and substance abuse (e.g., cannabis), especially during adolescence.
Social determinants of health (SDOH) may play a role in the development of this
condition. For example, clients of lower socioeconomic status or those forced to live in
areas of high chemical contamination or food deserts are more likely to experience or
have children who experience schizophrenia.
